Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

Disclosures: G.G. has acted as a consultant and received honoraria from Novartis and Bristol-Myers Squibb; F.C. has acted as a consultant for Novartis, Bristol-Myers Squibb and Pfizer and received honoraria from Novartis and Bristol-Myers Squibb; M. Breccia has acted as a consultant for Bristol-Myers Squibb and Novartis; M.T. has acted as consultant and received honoraria from Novartis, BMS and ARIAD; G.M. served on the speakers’ bureaus of Novartis, Bristol-Myers Squibb, and Pfizer; F.P. received research support from Novartis, served as advisor for Novartis, Bristol-Myers Squibb, and ARIAD Pharmaceuticals, and received lecture fees from Novartis and Bristol-Myers Squibb; G.S. has acted as a consultant for and received honoraria from Bristol-Myers Squibb, Novartis, ARIAD Pharmaceuticals, and Celgene; M. Baccarani received honoraria from Novartis, Bristol-Myers Squibb, Pfizer, and ARIAD Pharmaceuticals and served on the speakers’ bureaus of Novartis and Bristol Myers-Squibb; G.R. has acted as a consultant for Novartis, Bristol-Myers Squibb, and ARIAD Pharmaceuticals and served on the speakers’ bureaus of Novartis, Bristol-Myers Squibb, and Roche; the remaining Authors had no relevant conflicts of interest to disclose.

Contributions: G.G., M. Baccarani and G.R. analyzed the data and wrote the first draft of the manuscript. All the other authors contributed to the design of the study, to the collection of the data, and to the final report.